FOXO4-DRI
Also known as: FOXO4-D-Retro-Inverso, Proxofim
Senolytic Peptide | p53-FOXO4 Disruptor
Overview
FOXO4-DRI is a senolytic peptide designed to selectively eliminate senescent 'zombie' cells that accumulate with age and contribute to tissue dysfunction. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive. The 'DRI' modification (D-retro-inverso) uses reversed D-amino acids to increase potency and stability. Preclinical research shows restoration of fur density, fitness, and organ function in aged mice.
Key benefits
- Selective elimination of senescent cells
- Restoration of tissue homeostasis
- Improved fitness and physical function in aged models
- Restored fur density in aged mice
- Improved kidney function
- Alleviates chemotherapy-induced senescence
- Restores testosterone in aged males
- Reduces senescent chondrocytes in cartilage
- High selectivity spares healthy cells
Mechanism of action
FOXO4-DRI competes with FOXO4 for binding to p53, disrupting their protective interaction in senescent cells. This causes p53 to be excluded from the nucleus and triggers cell-intrinsic apoptosis (programmed cell death). Critically, this mechanism is highly selective: the FOXO4-p53 interaction is a specific vulnerability of senescent cells, while FOXO4 is minimally expressed in healthy tissues, leaving functional cells largely unharmed.
Molecular data
- Type
- D-retro-inverso peptide
- Half-life
- Not established
Indications
What the research community uses this compound for, with self-reported effectiveness.
Anti-Aging
Organ Function
Chemoprotection
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 25-33 mg | 3 doses, every other day (6 days total) | — |
| — | 5 mg/kg (translates to ~25 mg for 60kg human) | 3 doses on alternate days | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Limited human data available
- Generally well-tolerated in animal studies
Rare side effects
- Unknown - ongoing research
Contraindications
- Not yet approved for human use
- Pregnancy or breastfeeding
- Unknown safety in immunocompromised individuals
- Active cancer (theoretical - consult oncologist)
Monitoring
- Experimental peptide - medical supervision essential
- Monitor organ function during treatment
References
Primary literature and clinical-trial data informing this entry.